Fig. 2.

Genomic profiling of primary tumors and metastases.

A). Genomic profiling of primary tumors (upper panel) and metastases (lower panel). 20 most frequently altered genes are displayed. Alterations including SNVs, InDels, CNVs, and Fusions, are denoted with different colors. B). Prevalence of alterations in primary tumors and metastases. Deep deletions and mutations of tumor suppressors were integrated and labeled as “MutOrDel”. Fisher's exact tests were performed to compare the differences of prevalence in primary tumors and metastases. P values were adjusted for multiple comparisons with Benjamini and Hochberg method. Adjusted P values (q values) smaller than 0.05 were considered of statistical significance ***q < 0.005, **q < 0.01, *q < 0.05, ^.q < 0.1. Twenty alterations that showed significantly different prevalence between primaries and metastases are displayed in the descending order of metastatic prevalence. C). Tumor mutational burdens of samples from primary tumors and metastases to the lymph nodes, pleura, bone, liver, and brain. D). Chromosomal instability scores of samples from primary tumors and metastases to the lymph nodes, pleura, bone, liver, and brain. E). Prevalence of actionable alterations and selected oncogenic mutations in primary tumors and metastases. Alterations were ordered by their prevalence in metastases. P values were calculated and adjusted in the same way as (B). Adjusted P values (q values) smaller than 0.05 were considered of statistical significance ***q < 0.005, **q < 0.01, *q < 0.05, ^.q < 0.1. F). Proportions of tumor samples that harbored more than one actionable alteration, only one actionable alteration, and no actionable alteration, from primary tumors and metastases to the lymph nodes, pleura, bone, liver, and brain. G). Proportions of tumor samples that showed high PD-L1+ compositions (50% - 100%), low PD-L1+ compositions (1% - 49%), and no PD-L1+ composition (< 1%), from primary tumors and metastases to the lymph nodes, pleura, bone, liver, and brain. Abbreviations: MT – metastatic tumor, PT – primary tumor, TMB – tumor mutational burden, CIS – chromosomal instability score, LN – lymph node, PL – pleura, BN – bone, LV – liver, BR – brain, PD-L1 – programmed death ligand 1.